A detailed history of Advisor Group Holdings, Inc. transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 2,842 shares of TSVT stock, worth $8,923. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,842
Previous 3,330 14.65%
Holding current value
$8,923
Previous $12,000 8.33%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$3.85 - $5.05 $1,878 - $2,464
-488 Reduced 14.65%
2,842 $13,000
Q2 2024

Aug 13, 2024

SELL
$3.6 - $5.79 $52,581 - $84,568
-14,606 Reduced 81.43%
3,330 $12,000
Q1 2024

May 10, 2024

SELL
$3.09 - $6.0 $16,809 - $32,640
-5,440 Reduced 23.27%
17,936 $95,000
Q4 2023

Feb 12, 2024

BUY
$1.57 - $4.58 $18,818 - $54,895
11,986 Added 105.23%
23,376 $99,000
Q3 2023

Nov 13, 2023

BUY
$3.14 - $11.2 $19,301 - $68,846
6,147 Added 117.24%
11,390 $44,000
Q2 2023

Aug 21, 2023

SELL
$8.45 - $12.48 $464 - $686
-55 Reduced 1.04%
5,243 $53,000
Q2 2023

Aug 10, 2023

SELL
$8.45 - $12.48 $158,978 - $234,798
-18,814 Reduced 78.03%
5,298 $53,000
Q1 2023

May 12, 2023

BUY
$9.21 - $14.98 $190,379 - $309,651
20,671 Added 600.73%
24,112 $245,000
Q4 2022

Feb 10, 2023

SELL
$8.57 - $17.0 $368 - $731
-43 Reduced 1.23%
3,441 $32,000
Q3 2022

Nov 14, 2022

SELL
$12.56 - $17.54 $3,579 - $4,998
-285 Reduced 7.56%
3,484 $50,000
Q2 2022

Aug 10, 2022

BUY
$10.55 - $18.81 $29,666 - $52,893
2,812 Added 293.83%
3,769 $50,000
Q1 2022

May 04, 2022

BUY
$11.67 - $26.72 $11,168 - $25,571
957 New
957 $16,000

Others Institutions Holding TSVT

About 2seventy bio, Inc.


  • Ticker TSVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,873,600
  • Market Cap $119M
  • Description
  • 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...
More about TSVT
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.